News | October 11, 2021
Sai Life Sciences presents its midterm report
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Initially launched in Europe, this new service gives customers access to a range of digital health services and medical professionals and is part of its Digital Access to Care Initiative
The amalgamation is expected to bring in a lot of synergies in terms of operational efficiency and productivity for the combined entity
Proceeds raised from the duathlon will go towards cancer treatment of children identified by the hospital
Subscribe To Our Newsletter & Stay Updated
